SCHEMBL2260465

SCHEMBL2260465

COc1ccc2[nH]cc(CC(NC(=O)COc3cc(C(F)(F)F)nn3-c3ccccc3Cl)C(=O)O)c2c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.50
▸ POLB P06746 5/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ HTT P42858 1/20 0.50
▸ P2RY14 Q15391 1/20 0.49
▸ TP53 P04637 4/20 0.46
▸ ITGB2 P05107 2/20 0.45
▸ ICAM1 P05362 2/20 0.45
▸ ITGAL P20701 2/20 0.45
▸ MAPT P10636 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MMP2 P08253 1/20 0.44
▸ MMP13 P45452 1/20 0.44
▸ MMP14 P50281 1/20 0.44
▸ ADAM17 P78536 1/20 0.44
▸ GAA P10253 3/20 0.44
▸ LMNA P02545 1/20 0.43
▸ THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260468 1.00 KMT2A (0.50) KMT2APOLBMEN1HTTP2RY14
SCHEMBL2254827 0.87 MAPT (0.59) KMT2APOLBMEN1HTTP2RY14
SCHEMBL2261193 0.85 POLB (0.51) KMT2APOLBMEN1HTTP2RY14
SCHEMBL2261195 0.85 POLB (0.51) KMT2APOLBMEN1HTTP2RY14
SCHEMBL14177251 0.81 GPR34 (0.45) —
SCHEMBL2258570 0.80 MTNR1A (0.49) KMT2AMEN1MAPTGAA
SCHEMBL2256253 0.80 ADAM17 (0.41) KMT2APOLBMEN1HTTP2RY14
SCHEMBL2256252 0.80 ADAM17 (0.41) KMT2APOLBMEN1HTTP2RY14
SCHEMBL2257689 0.79 GPR34 (0.45) —
SCHEMBL14176937 0.78 TGFBR1 (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 — — US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069367-A1 LXR and FXR Modulators NR1H3, NR1H2, NR1H4 KMT2A 3296/4885POLB 4506/4885MEN1 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback